MedTrace Logo

Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector

NCT00738205 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 834

Last updated 2014-03-11

No results posted yet for this study

Summary

This is an international, multicenter study involving children treated with Saizen®, a growth hormone, who will be trained to use easypod, a new electronic injector and will complete a questionnaire after 12 week of use.

Both children naïve to growth hormone and dissatisfied with their current injection device will be recruited.

Conditions

  • Growth Hormone Deficiency
  • Turner Syndrome
  • Chronic Renal Failure
  • Small for Gestational Age

Sponsors & Collaborators

  • Merck KGaA, Darmstadt, Germany

    lead INDUSTRY

Principal Investigators

  • Clément Olivier, MD, LMCC · Merck Serono S.A., Geneva

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-03-31
Completion
2009-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00738205 on ClinicalTrials.gov